54814-29-8

Upstream product

• 7647-01-0 hydrogenchloride 
• 60-29-7 diethyl ether 
• 121986-07-0 p-nitromandelonitrile 
• 555-16-8 4-nitrobenzaldehdye 
• 71-43-2 benzene 
• 92-71-7 2,5-diphenyloxazole 

Downstream Products

• 1313744-67-0 (2S,2'S)-N,N'-(4,4'-(oxazole-2,5-diyl)bis(4,1-phenylene))bis(1-(2-phenylacetyl)pyrrolidine-2-carboxamide) 
• 1313750-92-3 (2S,2'S)-tert-butyl 2,2'-N,N′-(4,4'-(oxazole-2,5-diyl)bis(4,1-phenylene))bis(azanediyl)bis(oxomethylene)dipyrrolidine-1-carboxylate 
• 1313744-72-7 (2S,2'S)-N,N'-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(cyclopropylcarbonyl)-2-pyrrolidinecarboxamide) 
• 1313744-65-8 dibenzyl (2S,2'S)-2,2'-(1,3-oxazole-2,5-diylbis(4,1-phenylenecarbamoyl))di(1-pyrrolidinecarboxylate) 
• 118425-92-6 4,4'-(oxazole-2,5-diyl)dianiline 

Relevant academic research and scientific papers

Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons

A medicinal chemistry campaign that was conducted to address a potential genotoxic liability associated with an aniline-derived scaffold in a series of HCV NS5A inhibitors with dual GT-1a/-1b inhibitory activity is described. Anilides 3b and 3c were used

HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein